12 results
A Controlled Trial of Erenumab for Episodic Migraine #EBM #Neuro #Erenumab #Migraine #CGRP #VisualAbstract #NEJM
Episodic Migraine #EBM ... Erenumab #Migraine #CGRP ... VisualAbstract #NEJM
An AAV5 vector with a functional factor VIII gene tested in men with hemophilia A #EBM
hemophilia A #EBM ... #Honc #hemophilia ... VisualAbstract #NEJM
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free Survival #EBM ... #Honc #Osimertinib ... NSCLC #Survival #NEJM
Pembrolizumab Response Rate by Tumor Type #EBM #Honc #Pharm #Pembrolizumab #Response #TumorType #Colorectal #Endometrial #Biliary #NEJM
by Tumor Type #EBM ... #Honc #Pharm #Pembrolizumab ... Endometrial #Biliary #NEJM
IgM and Non-IgM - Risk and Type of Progression #EBM #Honc #MGUS #Progression #IgM #NonIgM #MultipleMyeloma
of Progression #EBM ... #Honc #MGUS #Progression ... MultipleMyeloma #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... Fremanezumab #Migraine #CGRP ... CalcitoninGeneRelatedPeptideAntibody #Results #NEJM ... #NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Non–Small-Cell Lung Cancer #EBM ... #Honc #Alectinib ... VisualAbstract #NEJM
Cumulative Incidence of Progression of MGUS, with Death Accounted for as a Competing Risk #EBM #Honc
Competing Risk #EBM ... #Honc #MGUS #Progression ... #IgG #MGUS #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Adverse Events in the Safety Population, According
to Trial Group #EBM ... Fremanezumab #Migraine #CGRP ... AdverseEvents #NEJM ... #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... Fremanezumab #Migraine #CGRP ... CalcitoninGeneRelatedPeptideAntibody #NEJM